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Abstract 
Currently the preferred anticonvulsant used to treat and prevent fits in eclampsia is magnesium sulphate. The main 
objective of this study was to evaluate the perinatal outcomes of magnesium sulphate and diazepam use in the 
management of severe pre-eclampsia and eclampsia in Jimma University Specialized Hospital. A retrospective 
hospital based cross-sectional comparative study was conducted using data collection format. Data was collected from 
the hospital delivery care register and patient chart records of all mothers who presented with the diagnosis of severe 
pre-eclampsia and eclampsia in two years and three months period from January, 2010 to April, 2012.  
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Descriptive analysis such as frequency and percentage, Chi-square test, binary logistic regression and non parametric 
tests were analyzed by SPSS version 16.0. A P-value of <0.05 was considered statistically significant in all tests. 
A total data of 343 births were included in this study. Two hundred seventeen from magnesium sulphate and one 
hundred forty from diazepam treated mothers group, were reviewed and analyzed.  There were ninety eight still births 
yielding a stillbirth rate of 24.5% and 35.1% for the magnesium sulphate and diazepam groups respectively. Fewer 
newborns in the magnesium sulphate treated group had Apgar scores less than seven than in the diazepam treated 
group at first and fifth minutes. A higher proportion of babies from the diazepam group were admitted to the neonatal 
ward than from the magnesium sulphate group (31.8% versus 18.1%). Birth outcome, first minute Apgar score and 
admission to the neonatal ward had a statistically significant association with the type of anticonvulsant used.  
Magnesium sulphate is more effective than diazepam in the management of severe pre-eclamptic and eclamptic 
mothers in terms of improving Apgar scores, reducing stillbirth outcome and admission to the neonatal ward. 
Therefore, its accessibility and wider use should be promoted.  
Keywords: Magnesium sulphate; diazepam; Severe pre-eclampsia; Eclampsia; perinatal outcome  
 
1. Introduction  
Pre-eclampsia is a condition unique to pregnancy that is characterized by new onset of hypertension and proteinuria in 
a previously normotensive woman [1]. It is a relatively common complication of pregnancy, and can occur at any time 
during the second half of pregnancy or in the first few weeks after delivery for many women who have pre-eclampsia 
perinatal outcome is good, but severe disease can lead to death or serious problems for her baby [2]. 
Pre-eclampsia and eclampsia are not distinct disorders but the manifestation of the spectrum of clinical symptoms of 
the same condition. In pre-eclampsia, hypertension and proteinuria are present, and when convulsions occur after other 
causes of convulsion are excluded in addition to these signs, the condition is referred to as eclampsia [1]. Eclampsia, 
characterized by maternal seizures, is a serious complication increasing the risk of maternal and perinatal morbidity 
and mortality [3]. 
Preeclampsia can be mild or severe. The mild one is defined as a blood pressure (BP) of at least 140/90 mmHg on at 
least two occasions in a minimum of 6 hours apart after the 20th week of gestation in women known to be 
normotensive before pregnancy plus proteinuria (300 mg or more per 24-hour period). If 24-hour urine collection is 
not available, then a concentration of at least 30 mg/dL (at least 1+ on dipstick) in at least two random urine samples 
collected at least 6 hours apart is defined proteinuria. Severe preeclampsia is defined as sustained elevations in systolic 
BP to at least 160 mmHg and/or in diastolic BP to at least 110 mmHg for at least 6 hours in association with abnormal 
proteinuria or if there is hypertension in association with severe proteinuria (at least 5 g per 24-hour period). In 
addition, preeclampsia is severe in the presence of multiorgan involvement such as pulmonary edema, oliguria (less 
than 500 mL per 24-hour period), thrombocytopenia (platelet count less than 100,000/ mm3), abnormal liver enzymes 
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in association with persistent epigastric or right upper quadrant pain, or persistent severe central nervous system 
symptoms (altered mental status, headaches, blurred vision or blindness) [4, 5]. 
Pre-eclampsia has remained a significant public health threat in both developed and developing countries contributing 
to maternal and perinatal morbidity and mortality globally. However, the impact of the disease is felt more severely in 
developing countries, where, unlike other more prevalent causes of maternal mortality (such as haemorrhage and 
sepsis), medical interventions may be ineffective due to late presentation of the cases. The problem is confounded by 
the continued mystery of the aetiology and the unpredictable nature of the disease [6]. 
Eclampsia occurs when pre-eclampsia is complicated by seizures or coma and it develops in 1 of 200 patients with 
pre-eclampsia. Eclampsia is immediately life threatening for both the baby and the mother and can be fatal if untreated 
[7]. 
Current strategies for prevention of pre-eclampsia can be broadly classified as antenatal surveillance, modification of 
lifestyle, nutritional supplementation, and pharmacological therapy. Currently, standard care for women with severe 
pre-eclampsia/eclampsia is to use an anticonvulsant drug to control the immediate fit, and to continue maintenance 
treatment to prevent further seizures [8].  
Currently, the preferred anticonvulsant is magnesium sulphate [9]. Large randomised trials in developing countries and 
systematic reviews have shown the usefulness of magnesium sulphate in treating recurrent eclamptic seizures and in 
the prophylaxis of eclampsia [10]. Over the last decade there has been an increase in the use of magnesium sulphate 
for the prevention of seizures in women with severe pre-eclampsia or eclampsia [11].   
In Ethiopia, magnesium sulphate is introduced as an anticonvulsant for treatment of severe pre-eclampsia and 
eclampsia.  Diazepam is still in use as an alternative in the absence of magnesium sulphate. It is used as 30 IU/ 1000 
ml of D/W, (D/S) 20 drops / min with an increase in the drops as needed depending on the patients’ sedation status [4, 
12]. 
Despite the use of different types of drugs, pre-eclampsia and eclampsia remain a massive cause of perinatal morbidity 
and mortality [3, 13]. 
Eclampsia is a common complication still associated with high level of perinatal mortality as well as morbidity in 
Ethioipia. The perinatal mortality rate of pre-eclampsia/eclampsia was 312.2/1000 deliveries in two teaching hospitals 
in Addis Ababa [14, 15]. In Jimma University Specialized hospital, severe pre-eclampsia was the most common 
hypertensive disorder of pregnancy followed by eclampsia contributing 51.9% and 23.4% of the cases respectively 
[16]. 
The Ethiopian Society of Obstetricians and Gynecologists has done a project from April 2009 to July 2011 to 
contribute towards the reduction of maternal mortality by introducing MgSO4 in all public hospitals in Ethiopia [17]. 
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However, there are no studies done to assess the impact of the drug on maternal and perinatal outcomes and compare it 
with diazepam after its introduction in public hospitals in Ethiopia in general and in Jimma University Specialized 
Hospital in particular. 
Magnesium sulphate has been included into the National Drug List of Ethiopia and is being used for prevention and 
treatment of severe pre-eclampsia and eclamptic seizures since January of 2011 in public hospitals though it’s still not 
in the List of Essential Drugs for Ethiopia (EDL).  
The study has brought findings to fill the information gap to what extent the drug affects perinatal outcomes as 
compared to diazepam since its introduction in our setting. 
2. Materials and methods 
This hospital based retrospective cross-sectional comparative study was conducted from mid-February to mid-April , 
2012 in Jimma University Specialized Hospital (JUSH), which is found in Jimma town. The hospital is one of the 
oldest public hospitals in the country and provides almost all major types of medical services such as Clinical services 
including Delivery and maternal and child health Services for approximately 9000 inpatient and 80000 outpatient 
attendants a year from the catchment population of about 15 million in southwest Ethiopia [18]. JUSH is the only 
teaching and referral hospital in the southwestern part of the country and has a total of more than 750 staffs of both 
supportive and professional with a total bed capacity of 450 [18] of which 47 are found in the maternity ward. The 
labor and maternity wards are run by midwives, medical and health officer interns, resident physicians of obstetrics 
and gynecology, and senior physicians of obstetrics and gynecology. JUSH has an ICU of eight beds with two 
anesthesiologists and various groups of residents and nurses.  
All newborns from mothers who admitted to JUSH maternity ward in the two years and three months period, from 
January 03, 2010 - April 02, 2012 were considered as source population and those whose mothers presented with the 
diagnosis of severe pre-eclampsia or eclampsia and took either magnesium sulphate or diazepam for prophylaxis or 
treatment of seizures were included in the study.  Newborns whose mothers were diagnosed with severe pre-eclampsia 
or eclampsia but died before taking diazepam or magnesium sulphate and those perinates whose mothers were referred 
from other health institutions taking any anticonvulsant before reaching the hospital were excluded in the study. 
Data was collected using a structured data collection format developed by the principal investigator after reviewing 
literatures and based on the objectives. The format consists of maternal details, diagnosis, type of anticonvulsants 
used, Apgar score of the baby at first and fifth minutes, admission status to the neonatal ward and other relevant 
information. 
The data collection format was pre-tested on 19 patient records (5%) in order to check any inconsistencies and 
necessary adjustments were made before the actual period of the study.  
The dependent variables were birth outcome (live birth, stillbirth), Apgar score at first and fifth minutes and admission 
to the neonatal ward. 
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Data was collected by a medical intern and a postgraduate clinical pharmacy student of Jimma University after 
orientation and training for three days. Data was obtained from the hospital delivery care register, Log Book and 
patient chart review. At the end of each day, the completeness and consistency of data collected was checked by the 
principal investigator. Then, the collected data was organized, cleaned, coded and analyzed by SPSS version 16.0 for 
windows.  
Chi-square test was used to determine the presence of association between the type of anticonvulsant used and the 
outcome variables. A binary logistic regression was done to assess the degree of association between type of 
anticonvulsant used and some perinatal outcome variables using odds ratio with 95% confidence interval. Mann-
whitney non-parametric test was employed to test the association of type of anticonvulsant used with Apgar score A P-
value of <0.05 was considered statistically significant for all the tests. 
Ethical clearance was granted from the college of Public Health and Medical sciences ethical review board (Ref. No 
RPGC/114/2012), Jimma University before data collection. Concerned bodies at all levels, including the hospital 
clinical director and department of obstetrics and gynecology, were communicated and approval was granted. Any 
personally identifiable information (e.g., name, address) was not recorded. Patient cards were returned to the card 
room after data collection. 
3. Results  
A total data of 343 births were included in this study. One hundred twenty six (35.3 %, n=357) and 231 (64.7%, 
n=357) mothers were diagnosed with eclampsia and severe pre-eclampsia respectively. Magnesium sulphate has been 
used as anticonvulsant for 217 (60.8%, n=357) mothers (table 1). 
Table 1: Maternal details admitted with the diagnosis of eclampsia and severe pre-eclampsia, JUSH, January 2010 – 
April 2012 (n=357). 
 
Maternal characteristics Frequency % 
Gravidity 
Primigravida  
Multigravida 
 
204 
153 
 
57.1 
42.9 
Maternal Diagnosis  
Severe Preeclampsia 
Eclampsia  
 
231 
126 
 
64.7 
35.3 
Type of anticonvulsant used 
Magnesium sulphate 
Diazepam  
 
217  
140 
 
60.8 
39.2 
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There were ninety eight still births, 52 (24.5%) (n=212) among magnesium sulphate and 46 (35.1%) (n=131) diazepam 
treated mothers. Birth outcome has a statistically significant association with the type of anticonvulsant used in severe 
pre-eclamptic mothers (P= 0.013) but not in eclamptic mothers (P= 0.952). Overall, birth outcome had a statistically 
significant association with the type of anticonvulsant used (P= 0.037) with (Table 2). 
 
Table 2: Association of birth outcome with type of anticonvulsant used from severe pre-eclamptic and eclamptic 
mothers, JUSH, January 2010 - April 2012 (n=343). 
 
 
Diagnosis 
 
Birth outcome 
Type of anticonvulsant used   
 p-value Magnesium sulphate 
(n=212)  
n (%) 
Diazepam 
(n=131) 
n (%) 
Total 
n (%) 
Severe pre-
eclampsia  
Still birth 
Live birth 
31 (20.9) 
117 (79.1) 
27 (36.5) 
47 (63.5) 
58 (26.1) 
164 (73.9) 
 
0.013 
Eclampsia  Still birth 
Live birth 
21 (32.8) 
43 (67.2) 
19 (33.3) 
38 (66.7) 
40 (33.1) 
81 (66.9) 
 
0.952 
Total  Still birth 
Live birth 
52 (24.5) 
160 (75.5) 
46 (35.5) 
85 (64.9) 
98 (28.6) 
245 (71.4) 
 
0.037 
 
The number of newborns, with a first minute Apgar score of less than seven, was fewer in mothers who were treated 
with magnesium sulphate than diazepam (42.5% versus 63.5%). First minute Apgar score was statistically significant 
with the type of anticonvulsant used (P=0.002) (table 3). However, fifth minute Apgar score was not statistically 
significant with the type of anticonvulsant used (P=0.275) though there was still fewer number of children with Apgar 
score less than seven (table 3). 
It was also recorded that there were 56 admissions to the neonatal ward. Twenty nine of perinates admitted to the 
neonatal ward were from mothers who had received magnesium sulphate as anticonvulsant. A higher proportion of 
babies from the mothers who received diazepam (18.1%, n=160) were admitted to the neonatal ward than from the 
magnesium sulphate received group (31.8%, n=85). A statistically significant association was found between perinatal 
admission to neonatal ward and type of anticonvulsant used (P=0.025) (table 5). 
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Table 3: Association of first minute Apgar score of perinates from severe pre-eclamptic and eclamptic mothers with 
type of anticonvulsant used, JUSH, January 2010 - April 2012. 
 
Diagnosis 
 
First minute 
Apgar score 
Type of anticonvulsant used   
p-value Magnesium sulphate 
(n=160)  
n (%) 
Diazepam 
(n=85) 
n (%) 
Total 
n (%) 
Severe pre-
eclampsia  
< seven  
>seven 
37 (33.9) 
72 (66.1) 
30 (60.0) 
20 (40.0) 
67 (42.1) 
92 (57.9) 
 
0.002 
Eclampsia  < seven  
>seven 
31 (60.8) 
20 (39.2) 
24 (68.6) 
11 (31.4) 
31 (64.0) 
55 (36.0) 
 
0.460 
Total  < seven  
>seven 
68 (42.5) 
92 (57.5) 
54 (63.5) 
31 (36.5) 
122 (49.8) 
123 (50.2) 
 
0.002 
 
 
Table 4: Association of fifth minute Apgar score of perinates from severe pre-eclamptic and eclamptic mothers with 
type of anticonvulsant used, JUSH, January 2010 - April 2012. 
 
Type of anticonvulsant 
Fifth minute Apgar score   
P-valve 
 
< seven > seven 
Frequency      %   Frequency      % 
Magnesium sulphate 23 14.4 137 85.6  
0.275 Diazepam  16 18.2 69 81.8 
Total 39 15.9 206 84.1 
 
Binary logistic regression analysis indicated that the likelihood of stillbirth birth outcome, perinates having an Apgar 
score of less than seven and admission of perinates to the neonatal ward in the magnesium sulphate treated mothers 
was 0.601, 0.424 and 0.484 times their counterparts in the diazepam treated group respectively (table 6). 
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Table 5: Association of perinatal admission to the neonatal ward with type of anticonvulsant used among newborns 
from severe pre-eclamptic and eclamptic mothers, JUSH, January 2010 - April 2012. 
 
Diagnosis 
 
Admission to the 
neonatal ward  
Type of anticonvulsant used   
p-value Magnesium sulphate 
(n=160)  
n (%) 
Diazepam 
(n=85) 
n (%) 
Total 
n (%) 
Severe pre-
eclampsia  
Yes 
No 
20 (18.3) 
89 (81.7) 
11 (26.2) 
31 (73.8) 
31 (20.5) 
120 (79.5) 
 
0.039 
Eclampsia  Yes 
No 
9 (-) 
42 (82.4) 
16 (36.4) 
26 (63.6) 
25 (26.3) 
70 (73.7) 
 
0.025  
Total  Yes 
No 
29 (18.1) 
131 (81.9) 
27 (31.8) 
58 (68.2) 
56 (22.9) 
189 (77.1) 
 
0.028 
 
 
Table 6: Binary logistic regression of some outcome variables with type of anticonvulsant used, JUSH, January 2010 - 
April 2012.  
Type of anticonvulsant Outcome variable p-value OR 95% CI 
 
Magnesium sulphate 
Diazepam 
Still Birth outcome 
52 
46 
 
0.036 
 
 
0.601 
1 
 
0.373-0.967 
Reference 
 
Magnesium sulphate 
Diazepam 
First minute Apgar score<7 
68 
54 
 
0.002 
 
 
0.424 
1 
 
0.247-0.729 
Reference 
 
Magnesium sulphate 
Diazepam 
Neonatal ward admission 
29 
27 
 
0.019 
 
 
0.484 
1 
 
0.263-0.888 
Reference 
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4. Discussion 
The current study has attempted to compare the perinatal outcomes of magnesium sulphate use with diazepam in terms 
of birth outcome, first and fifth minute Apgar scores, and admission to the perinatal ward.  
It has been revealed, in a typical systematic quantitative review and analysis, that magnesium sulphate was more 
effective than other interventions in preventing recurrent seizures in eclampsia and in preventing the first seizure in 
pre-eclampsia so that improves perinatal outcomes [5].  
Eclampsia and pre-eclampsia are among the hypertensive disorders of pregnancy that result high rate of stillbirth. In 
this study, the stillbirth rate in magnesium sulphate treated mothers is lower than in diazepam treated mothers {(24.5% 
versus 35.1%) (OR 0.601, 95% CI 0.373 to 0.967)} yielding a total stillbirth rate of 285.7 per 1000 births. This finding 
is more or less consistent with other Literatures that support use of magnesium sulphate resulted in a lower stillbirth 
rate than diazepam [9, 19]. A study done in a teaching hospital in Nigeria (2010) showed a stillbirth rate of 368.4 per 
1000 births among those treated with diazepam and 296.7 per 1000 births in the magnesium sulphate group [20]. 
According to a study done in Jimma University specialized hospital on hypertensive disorders of pregnancy the 
stillbirth rate was 27.5% [16]. The stillbirth rate in this study was found to be higher as eclampsia and severe pre-
eclampsia are relatively more severe forms than other hypertensive disorders of pregnancy.    
This study revealed that there were fewer newborns with low first minute Apgar score from magnesium sulphate 
treated mothers than from diazepam treated mothers (42.5% versus 63.5%). This could be explained by the fact that 
diazepam causes respiratory depression to the perinate. This finding is supported by other several studies such as the 
Ikramullah et al study in 2009 [21]. Crowther’s study on Magnesium sulphate versus diazepam in the management of 
eclampsia showed that Significantly fewer infants born in the magnesium sulphate group had low Apgar scores (less 
than 7 at 1 min) compared with those in the diazepam group (RR 0.6; 95% CI 0.4 to 0.9) [19].This has also been 
observed that in the magnesium sulphate group, fewer live born babies had an Apgar score less than seven at one 
minute (two trials; 597 babies; RR 0.75, 95% CI 0.65 to 0.87) or at five minutes (RR 0.70, 95% CI 0.54 to 0.90) in the 
Cochrane study (2010) [22].  
Regarding admission to the neonatal ward fewer babies from the magnesium sulphate treated mothers group were 
admitted to the neonatal ward than from the diazepam treated group {(18.1% versus 31.8%)(OR 0.484, 95% CI 0.263 
to 0.888)}. The admission rate in this study is lower as compared to other studies such as a study done in America by 
Greenberg MB et al in 2011 where 21.1% of neonates whose mothers had been exposed to antenatal magnesium 
sulphate were admitted to the NICU [23]. Admission of newborns from magnesium sulphate treated mothers; to 
special care baby unit in the Magpie Trial Collaborative Group was 39% [24]. This could be due to limited space in 
the neonatal ward as JUSH is the only referral hospital in the area. But still the findings agree with other studies in 
terms of reducing perinatal admission to special care unit and there are some studies with a lower admission rate than 
this study in Nepal and Pakistan [21, 25]. 
5. Limitations of the study    
The main limitation of this study was being retrospective and its dependence on patients' records. Because of this it 
was not possible to include the actual drug administration issues and outcomes of the infant after admission to the 
perinatal ward. Some patient cards did not contain all necessary information that affected the quality of the study. We 
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has also assumed that patients' management (dose, frequency of administration, etc) in either group was strictly in line 
with the hospital's protocol as we were unable to check it prospectively.  
6. Conclusion  
This study has shown a reduction in the number of newborns with low first minute Apgar scores from severe pre-
eclamptic mothers who received magnesium sulphate as compared to those newborns from mothers who received 
diazepam as anticonvulsant. Admission of perinates to the neonatal ward from severe pre-eclamptic and eclamptic 
mothers was found to be higher in the diazepam treated group than magnesium sulphate treated group. There was also 
a reduction in still birth rate of newborns from mothers who received magnesium sulphate as compared to those 
newborns from mothers who received diazepam. 
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